C. J. Phillips, The Cost and Burden of Chronic Pain, Rev. Pain, vol.3, pp.2-5, 2009.

H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher, Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment, Eur. J. Pain, vol.10, pp.287-333, 2006.

, American Academy of Pain Medicine. Management of chronic pain syndromes: Issues and interventions, Pain Med, vol.6, pp.1-21, 2005.

B. Nicholson, E. Ross, A. Weil, J. Sasaki, and G. Sacks, Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules, Curr. Med. Res. Opin, vol.22, pp.539-550, 2006.

S. Deandrea, M. Montanari, L. Moja, and G. Apolone, Prevalence of undertreatment in cancer pain. A review of published literature, Ann. Oncol, vol.19, 1985.

J. W. Geurts, P. C. Willems, C. Lockwood, M. Van-kleef, J. Kleijnen et al., Patient expectations for management of chronic non-cancer pain: A systematic review, vol.20, pp.1201-1217, 2017.

I. Melnikova, Pain market, Nat. Rev. Drug Discov, vol.9, pp.589-590, 2010.

D. Borsook, R. Hargreaves, C. Bountra, and F. Porreca, Lost but making progress-Where will new analgesic drugs come from?, Sci. Transl. Med, vol.6, 2014.

P. Stern and L. Roberts, The future of pain research, Science, vol.354, pp.564-565, 2016.

P. Skolnick, The Opioid Epidemic: Crisis and Solutions, Annu. Rev. Pharmacol. Toxicol, vol.58, pp.143-159, 2018.

A. I. Basbaum and T. Jessell, The Perception of Pain, Neural Sciences

E. R. Kandel and J. Schwartz, , pp.472-491, 2000.

A. I. Basbaum, D. M. Bautista, G. Scherrer, and D. Julius, Cellular and molecular mechanisms of pain, Cell, vol.139, pp.267-284, 2009.

C. J. Woolf and Q. Ma, Nociceptors-noxious stimulus detectors, Neuron, vol.55, pp.353-364, 2007.

A. E. Dubin and A. Patapoutian, Nociceptors: The sensors of the pain pathway, J. Clin. Investig, vol.120, pp.3760-3772, 2010.

R. R. Ji, A. Chamessian, and Y. Q. Zhang, Pain regulation by non-neuronal cells and inflammation, Science, vol.354, pp.572-577, 2016.

C. Abbadie, S. Bhangoo, Y. De-koninck, M. Malcangio, S. Melik-parsadaniantz et al., Chemokines and pain mechanisms, Brain Res, vol.60, pp.125-134, 2009.

S. H. Ferreira, B. B. Lorenzetti, A. F. Bristow, and S. Poole, Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue, Nature, vol.334, pp.698-700, 1988.

C. J. Woolf, A. Allchorne, B. Safieh-garabedian, and S. Poole, Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor alpha, Br. J. Pharmacol, vol.121, pp.417-424, 1997.

S. B. Mcmahon, F. La-russa, and D. L. Bennett, Crosstalk between the nociceptive and immune systems in host defence and disease, Nat. Rev. Neurosci, vol.16, pp.389-402, 2015.

G. A. Fitzgerald, Correction: Cox-2 and beyond: Approaches to prostagland in inhibition in human disease, Nat. Rev. Drug Discov, vol.2, 1030.

P. Baral, S. Udit, and I. M. Chiu, Pain and immunity: Implications for host defence, Nat. Rev. Immunol, 2019.

F. A. Pinho-ribeiro, W. A. Verri, . Jr, and I. M. Chiu, Nociceptor Sensory Neuron-Immune Interactions in Pain and Inflammation, Trends Immunol, vol.38, pp.5-19, 2017.

D. Julius and J. Nathans, Signaling by sensory receptors, Cold Spring Harb. Perspect. Biol, 2012.

A. Khan, S. Khan, and Y. S. Kim, Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets, Curr. Drug Targets, vol.20, pp.775-788, 2019.

M. Costigan and C. J. Woolf, Pain: Molecular mechanisms, J. Pain, vol.1, pp.35-44, 2000.

B. O. Gohlke, R. Preissner, and S. Preissner, SuperPain-a resource on pain-relieving compounds targeting ion channels, Nucleic Acids Res, vol.42, pp.1107-1112, 2014.

T. Rouwette, L. Avenali, J. Sondermann, P. Narayanan, D. Gomez-varela et al., Modulation of nociceptive ion channels and receptors via protein-protein interactions: Implications for pain relief, Channels, vol.9, pp.175-185, 2015.

C. D. Benham, J. B. Davis, and A. D. Randall, Vanilloid and TRP channels: A family of lipid-gated cation channels, Neuropharmacology, vol.42, pp.873-888, 2002.

H. A. Blair, Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain, Drugs, vol.78, pp.1489-1500, 2018.

I. Nozadze, N. Tsiklauri, G. Gurtskaia, and M. G. Tsagareli, NSAIDs attenuate hyperalgesia induced by TRP channel activation, Data Brief, vol.6, pp.668-673, 2016.

H. Machelska and M. O. Celik, Advances in Achieving Opioid Analgesia Without Side Effects, Front. Pharmacol, vol.9, 1388.

U. Anand, P. Facer, Y. Yiangou, M. Sinisi, M. Fox et al., Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons, Eur. J. Pain, vol.17, pp.1012-1026, 2013.

A. S. Rice, R. H. Dworkin, T. D. Mccarthy, P. Anand, C. Bountra et al., EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: A randomised, double-blind, placebo-controlled phase 2 clinical trial, Lancet, vol.383, pp.1637-1647, 2014.

M. T. Smith and A. Muralidharan, Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain, Expert Opin. Ther. Targets, vol.19, pp.25-35, 2015.

A. S. Yekkirala, D. P. Roberson, B. P. Bean, and C. J. Woolf, Breaking barriers to novel analgesic drug development, Nat. Rev. Drug Discov, vol.16, 2017.

J. N. Wood, Results in analgesia-Darwin 1, pharma 0, N. Engl. J. Med, vol.369, pp.2558-2560, 2013.

J. Kou, Y. Ni, N. Li, J. Wang, L. Liu et al., Analgesic and anti-inflammatory activities of total extract and individual fractions of Chinese medicinal ants Polyrhachis lamellidens, Biol. Pharm. Bull, vol.28, pp.176-180, 2005.

Y. Maatuf, M. Geron, and A. Priel, The Role of Toxins in the Pursuit for Novel Analgesics, Toxins, vol.11, 2019.

F. Yang and J. Zheng, Understand spiciness: Mechanism of TRPV1 channel activation by capsaicin, Protein Cell, vol.8, pp.169-177, 2017.

W. Poewe, P. Burbaud, G. Castelnovo, W. H. Jost, A. O. Ceballos-baumann et al., Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial, Mov. Disord, vol.31, pp.1649-1657, 2016.

C. Tassorelli, M. Aguggia, M. De-tommaso, P. Geppetti, L. Grazzi et al., Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: Results of a survey of sixty-three Italian headache centers, J. Headache Pain, vol.18, 2017.

R. J. Lewis, Conotoxins as selective inhibitors of neuronal ion channels, receptors and transporters, IUBMB Life, vol.56, pp.89-93, 2004.

A. Hama and J. Sagen, Antinociceptive effects of the marine snail peptides conantokin-G and conotoxin MVIIA alone and in combination in rat models of pain, Neuropharmacology, vol.56, pp.556-563, 2009.

A. B. Malmberg, H. Gilbert, R. T. Mccabe, and A. I. Basbaum, Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T, vol.101, pp.109-116, 2003.

R. R. Yotsu, M. Richardson, and N. Ishii, Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease), Cochrane Database Syst. Rev, vol.8, 2018.

K. M. George, D. Chatterjee, G. Gunawardana, D. Welty, J. Hayman et al., A polyketide toxin from Mycobacterium ulcerans required for virulence, vol.283, pp.854-857, 1999.

S. Sinha, A. J. Schreiner, J. Biernaskie, D. Nickerson, and V. A. Gabriel, Treating pain on skin graft donor sites: Review and clinical recommendations, J. Trauma Acute Care Surg, vol.83, pp.954-964, 2017.

Q. B. Vincent, M. F. Ardant, A. Adeye, A. Goundote, J. P. Saint-andre et al., Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: A cohort study. Lancet Glob. Health, vol.2, 2014.

P. D. Johnson, T. Stinear, P. L. Small, G. Pluschke, R. W. Merritt et al., Buruli ulcer (M. ulcerans infection): New insights, new hope for disease control, PLoS Med, vol.2, 2005.

V. Sizaire, F. Nackers, E. Comte, and F. Portaels, Mycobacterium ulcerans infection: Control, diagnosis, and treatment, Lancet Infect. Dis, vol.6, pp.288-296, 2006.

J. En, M. Goto, K. Nakanaga, M. Higashi, N. Ishii et al., Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (Buruli ulcer) in a murine study, Infect. Immun, vol.76, 2002.

E. Marion, O. R. Song, T. Christophe, J. Babonneau, D. Fenistein et al., Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways, Cell, vol.157, pp.1565-1576, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01117565

J. Babonneau, D. Breard, M. L. Reynaert, E. Marion, D. Guilet et al., Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters, Front. Pharmacol, vol.10, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02100552

B. Hall and R. Simmonds, Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer, Biochem. Soc. Trans, vol.42, pp.177-183, 2014.

F. S. Sarfo, R. Phillips, M. Wansbrough-jones, and R. E. Simmonds, Recent advances: Role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease, Cell. Microbiol, vol.18, pp.17-29, 2016.

J. Ogbechi, B. S. Hall, T. Sbarrato, J. Taunton, A. E. Willis et al., Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4, Cell Death Dis, vol.9, 2018.

K. Asiedu, R. Scherpbier, and M. Raviglione, Buruli ulcer: Mycobacterium Ulcerans Infection, p.20, 2019.

T. S. Van-der-werf, W. T. Van-der-graaf, J. W. Tappero, and K. Asiedu, Mycobacterium ulcerans infection, Lancet, vol.354, pp.1013-1018, 1999.

C. Demangel and S. High, Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease, Biol. Cell, vol.110, pp.237-248, 2018.

L. Guenin-mace, R. Veyron-churlet, M. I. Thoulouze, G. Romet-lemonne, H. Hong et al., Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation, J. Clin. Investig, vol.123, pp.1501-1512, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-00874628

L. Baron, A. O. Paatero, J. D. Morel, F. Impens, L. Guenin-mace et al., Mycolactone subverts immunity by selectively blocking the Sec61 translocon, J. Exp. Med, vol.213, pp.2885-2896, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-01432024

L. Guenin-mace, L. Baron, A. C. Chany, C. Tresse, S. Saint-auret et al., Shaping mycolactone for therapeutic use against inflammatory disorders, Sci. Transl. Med, vol.7, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-01382767

C. Isaac, A. Mauborgne, A. Grimaldi, K. Ade, M. Pohl et al., Mycolactone displays anti-inflammatory effects on the nervous system, PLoS Negl. Trop. Dis, vol.11, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01664214

R. Bieri, N. Scherr, M. T. Ruf, J. P. Dangy, P. Gersbach et al., The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR, ACS Chem. Biol, vol.12, pp.1297-1307, 2017.

S. K. Kwofie, B. Dankwa, K. S. Enninful, C. Adobor, E. Broni et al., Molecular Docking and Dynamics Simulation Studies Predict Munc18b as a Target of Mycolactone: A Plausible Mechanism for Granule Exocytosis Impairment in Buruli Ulcer Pathogenesis, Toxins, vol.11, p.181, 2019.

M. Goto, K. Nakanaga, T. Aung, T. Hamada, N. Yamada et al., Nerve damage in Mycobacterium ulcerans-infected mice: Probable cause of painlessness in buruli ulcer, Am. J. Pathol, vol.168, pp.805-811, 2006.

M. Ocana, C. M. Cendan, E. J. Cobos, J. M. Entrena, and J. M. Baeyens, Potassium channels and pain: Present realities and future opportunities, Eur. J. Pharmacol, vol.500, pp.203-219, 2004.

K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris, A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia, Pain, vol.32, pp.77-88, 1988.

O. R. Song, H. B. Kim, S. Jouny, I. Ricard, A. Vandeputte et al., A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone, Toxins, vol.9, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01582485

M. B. Maciver, S. M. Amagasu, A. A. Mikulec, and F. A. Monroe, Riluzole anesthesia: Use-dependent block of presynaptic glutamate fibers, Anesthesiology, vol.85, pp.626-634, 1996.

F. Duprat, F. Lesage, A. J. Patel, M. Fink, G. Romey et al., The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK, Mol. Pharmacol, vol.57, pp.906-912, 2000.

J. Noel, K. Zimmermann, J. Busserolles, E. Deval, A. Alloui et al., The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception, EMBO J, vol.28, pp.1308-1318, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00418382

A. Mathie and E. L. Veale, Two-pore domain potassium channels: Potential therapeutic targets for the treatment of pain. Pflügers Arch, vol.467, pp.931-943, 2015.

D. Fornasari, Pain pharmacology: Focus on opioids. Clin. Cases Miner, Bone Metab, vol.11, pp.165-168, 2014.

I. Szelenyi, Flupirtine, a re-discovered drug, revisited, Inflamm. Res, vol.62, pp.251-258, 2013.

H. Zhang, G. W. Han, A. Batyuk, A. Ishchenko, K. L. White et al., Structural basis for selectivity and diversity in angiotensin II receptors, Nature, vol.544, pp.327-332, 2017.

A. H. Danser and P. Anand, The angiotensin II type 2 receptor for pain control, Cell, vol.157, pp.1504-1506, 2014.

U. Anand, Y. Yiangou, M. Sinisi, M. Fox, A. Macquillan et al., Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: Clinical tissue and in vitro studies, Mol. Pain, vol.11, 2015.

M. T. Smith, P. Anand, and A. S. Rice, Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: Preclinical and clinical studies, Pain, vol.2016, pp.33-41

U. Anand, M. Sinisi, M. Fox, A. Macquillan, T. Quick et al., Mycolactone-mediated neurite degeneration and functional effects in cultured human and rat DRG neurons: Mechanisms underlying hypoalgesia in Buruli ulcer, Mol. Pain, vol.12, 2016.

Y. Wan, C. Wallinder, B. Plouffe, H. Beaudry, A. K. Mahalingam et al., Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist, J. Med. Chem, vol.47, pp.5995-6008, 2004.

B. Frias, A. Merighi, and . Capsaicin, Nociception and Pain. Molecules, vol.21, 2016.

Y. Takayama, D. Uta, H. Furue, and M. Tominaga, Pain-enhancing mechanism through interaction between TRPV1 and anoctamin 1 in sensory neurons, Proc. Natl. Acad. Sci, vol.112, pp.5213-5218, 2015.

P. Anand and K. Bley, Topical capsaicin for pain management: Therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch, Br. J. Anaesth, vol.107, pp.490-502, 2011.

S. Benitez, A. Seltzer, and C. Acosta, Nociceptor-like rat dorsal root ganglion neurons express the angiotensin-II AT2 receptor throughout development, Int. J. Dev. Neurosci, vol.56, pp.10-17, 2017.

A. J. Shepherd, B. A. Copits, A. D. Mickle, P. Karlsson, S. Kadunganattil et al., Angiotensin II Triggers Peripheral Macrophage-to-Sensory Neuron Redox Crosstalk to Elicit Pain, J. Neurosci, vol.38, pp.7032-7057, 2018.

E. Coutanceau, L. Marsollier, R. Brosch, E. Perret, P. Goossens et al., Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: The contribution of endogenous mycolactone toxin, Cell. Microbiol, vol.7, pp.1187-1196, 2005.

B. S. Hall, K. Hill, M. Mckenna, J. Ogbechi, S. High et al., The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER, PLoS Pathog, vol.10, 2014.

M. Mckenna, R. E. Simmonds, and S. High, Mechanistic insights into the inhibition of Sec61-dependent co-and post-translational translocation by mycolactone, J. Cell Sci, vol.129, pp.1404-1415, 2016.

J. Ogbechi, M. T. Ruf, B. S. Hall, K. Bodman-smith, M. Vogel et al., Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions, PLoS Pathog, vol.11, 2015.

J. D. Morel, A. O. Paatero, J. Wei, J. W. Yewdell, L. Guenin-mace et al., Proteomics Reveals Scope of Mycolactone-mediated Sec61 Blockade and Distinctive Stress Signature, Mol. Cell Proteom, vol.17, pp.1750-1765, 2018.

D. H. Connor and H. F. Lunn, Mycobacterium ulcerans infection (with comments on pathogenesis), Int. J. Infect. Dis, vol.33, pp.698-709, 1965.

K. M. George, L. P. Barker, D. M. Welty, and P. L. Small, Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans, Infect. Immun, vol.66, pp.587-593, 1998.

H. Hong, P. J. Gates, J. Staunton, T. Stinear, S. T. Cole et al., Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans, Chem. Commun, pp.2822-2823, 2003.

E. Marion, S. Prado, C. Cano, J. Babonneau, S. Ghamrawi et al., Photodegradation of the Mycobacterium ulcerans toxin, mycolactones: Considerations for handling and storage, PLoS ONE, vol.7, 2012.

F. S. Sarfo, F. Le-chevalier, N. Aka, R. O. Phillips, Y. Amoako et al., Mycolactone diffuses into the peripheral blood of Buruli ulcer patients-implications for diagnosis and disease monitoring, PLoS Negl. Trop. Dis, 1237.
URL : https://hal.archives-ouvertes.fr/inserm-00691438

F. S. Sarfo, R. O. Phillips, J. Zhang, M. K. Abass, J. Abotsi et al., Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease, BMC Infect. Dis, vol.14, 2014.

G. Gunawardana, D. Chatterjee, K. M. George, P. Brennan, D. Whittern et al., Characterization of Novel Macrolide Toxins, Mycolactones A and B, from a Human Pathogen, Mycobacterium ulcerans, J. Am. Chem. Soc, vol.121, pp.6092-6093, 1999.

V. Fattori, A. C. Zarpelon, L. Staurengo-ferrari, S. M. Borghi, T. H. Zaninelli et al., Budlein A, a Sesquiterpene Lactone from Viguiera robusta, Alleviates Pain and Inflammation in a Model of Acute Gout Arthritis in Mice, Front. Pharmacol, vol.9, 1076.

M. Ahmad, F. Saeed, and . Mehjabeen,

N. Jahan, Neuro-pharmacological and analgesic effects of Arnica montana extract, Int. J. Pharm. Pharm. Sci, vol.5, pp.590-593, 2013.

R. Gounder, Kava consumption and its health effects. Pac. Health Dialog, vol.13, pp.131-135, 2006.

A. El-mahmoudy and I. Gheith, The anti-nociceptive potential of tilmicosin against chemical-induced but not thermal-induced pain in mice, Int. J. Immunopathol. Pharmacol, vol.29, pp.9-16, 2016.

F. Portaels, K. Chemlal, P. Elsen, P. D. Johnson, J. A. Hayman et al., Mycobacterium ulcerans in wild animals, Rev. Sci. Tech, vol.20, pp.252-264, 2001.

T. P. Stinear, A. Mve-obiang, P. L. Small, W. Frigui, M. J. Pryor et al., Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans, Proc. Natl. Acad. Sci, vol.101, pp.1345-1349, 2004.

J. L. Porter, N. J. Tobias, S. J. Pidot, S. Falgner, K. L. Tuck et al., The cell wall-associated mycolactone polyketide synthases are necessary but not sufficient for mycolactone biosynthesis, PLoS ONE, vol.8, 2013.

J. Z. Kubicek-sutherland, D. M. Vu, A. S. Anderson, T. C. Sanchez, P. J. Converse et al., Understanding the Significance of Biochemistry in the Storage, Handling, Purification, and Sampling of Amphiphilic Mycolactone, Toxins, vol.11, 2019.

H. Hong, J. B. Spencer, J. L. Porter, P. F. Leadlay, and T. Stinear, A novel mycolactone from a clinical isolate of Mycobacterium ulcerans provides evidence for additional toxin heterogeneity as a result of specific changes in the modular polyketide synthase, Chembiochem, vol.6, pp.643-648, 2005.

A. Mve-obiang, R. E. Lee, F. Portaels, and P. L. Small, Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: Implications for virulence, Infect. Immun, vol.71, pp.774-783, 2003.

Y. Kishi, Chemistry of mycolactones, the causative toxins of Buruli ulcer, Proc. Natl. Acad. Sci, vol.108, pp.6703-6708, 2011.

S. Fidanze, F. Song, M. Szlosek-pinaud, P. L. Small, and Y. Kishi, Complete Structure of the Mycolactones, J. Am. Chem. Soc, vol.123, pp.10117-10118, 2001.

A. Mve-obiang, R. E. Lee, E. S. Umstot, K. A. Trott, T. C. Grammer et al., A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin, Infect. Immun, vol.73, pp.3307-3312, 2005.

M. J. Yip, J. L. Porter, J. A. Fyfe, C. J. Lavender, F. Portaels et al., Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor, J. Bacteriol, vol.189, pp.2021-2029, 2007.

M. Yoshida, Y. Miyamoto, Y. Ogura, T. Hayashi, and Y. Hoshino, Complete Chromosome Sequence of a Mycolactone-Producing Mycobacterium, Mycobacterium pseudoshottsii, Genome Announc, vol.5, pp.1363-1380, 2017.

S. J. Pidot, K. Asiedu, M. Kaser, J. A. Fyfe, and T. P. Stinear, Mycobacterium ulcerans and other mycolactone-producing mycobacteria should be considered a single species, PLoS Negl. Trop. Dis, 2010.

R. Cregg, G. Russo, A. Gubbay, R. Branford, and H. Sato, Pharmacogenetics of analgesic drugs, Br. J. Pain, vol.7, pp.189-208, 2013.

P. Gersbach, A. Jantsch, F. Feyen, N. Scherr, J. P. Dangy et al., A ring-closing metathesis (RCM)-based approach to mycolactones A/B, Chemistry, vol.17, pp.13017-13031, 2011.

A. C. Chany, V. Casarotto, M. Schmitt, C. Tarnus, L. Guenin-mace et al., A diverted total synthesis of mycolactone analogues: An insight into Buruli ulcer toxins, Chemistry, vol.17, pp.14413-14419, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02128753

M. Gehringer and K. H. Altmann, The chemistry and biology of mycolactones, Beilstein J. Org. Chem, vol.13, pp.1596-1660, 2017.

N. Scherr, P. Gersbach, J. P. Dangy, C. Bomio, J. Li et al., Structure-activity relationship studies on the macrolide exotoxin mycolactone of Mycobacterium ulcerans, PLoS Negl. Trop. Dis, 2013.

H. Hong, T. Stinear, J. Porter, C. Demangel, and P. F. Leadlay, A novel mycolactone toxin obtained by biosynthetic engineering, Chembiochem, vol.8, pp.2043-2047, 2007.

A. H. Rowe, Y. Xiao, M. P. Rowe, T. R. Cummins, and H. H. Zakon, Voltage-gated sodium channel in grasshopper mice defends against bark scorpion toxin, Science, vol.342, pp.441-446, 2013.

L. Guenin-macé, M. Ruf, G. Pluschke, and C. Demangel, Mycolactone: More than Just a Cytotoxin, Buruli ulcer: Mycobacterium Ulcerans Disease

G. Pluschke and K. Röltgen, , pp.117-134, 2019.

L. Marsollier, T. Stinear, J. Aubry, J. P. Saint-andre, R. Robert et al., Aquatic plants stimulate the growth of and biofilm formation by Mycobacterium ulcerans in axenic culture and harbor these bacteria in the environment, Appl. Environ. Microbiol, vol.70, pp.1097-1103, 2004.

L. Marsollier, P. Brodin, M. Jackson, J. Kordulakova, P. Tafelmeyer et al., Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis, PLoS Pathog, vol.3, 2007.

T. H. Senanayake, Y. Lu, A. Bohling, S. Raja, H. Band et al., Encapsulation of poorly soluble drugs in polymer-drug conjugates: Effect of dual-drug nanoformulations on cancer therapy, Pharm. Res, vol.31, pp.1605-1615, 2014.

R. J. Lewis, S. Dutertre, I. Vetter, and M. J. Christie, Conus venom peptide pharmacology, Pharmacol. Rev, vol.64, pp.259-298, 2012.

J. G. Mcgivern, Ziconotide: A review of its pharmacology and use in the treatment of pain, Neuropsychiatr. Dis. Treat, vol.3, pp.69-85, 2007.

M. Kumar, R. Chawla, and M. Goyal, Topical anesthesia, J. Anaesthesiol. Clin. Pharmacol, vol.31, pp.450-456, 2015.

H. Groninger and R. E. Schisler, Topical capsaicin for neuropathic pain #255, J. Palliat. Med, vol.15, pp.946-947, 2012.

Z. El-maddawy, El-Ashmawy, I. Hepato-Renal and Hematological Effects of Diclofenac Sodium in Rats, Glob. J. Pharmacol, vol.7, pp.123-132, 2013.

L. J. Wrighton, K. R. O'bosky, J. P. Namm, and M. Senthil, Postoperative management after hepatic resection, World J. Gastrointest. Oncol, vol.3, pp.41-47, 2012.

C. R. Chapman, G. W. Donaldson, J. J. Davis, and D. H. Bradshaw, Improving individual measurement of postoperative pain: The pain trajectory, J. Pain, vol.12, pp.257-262, 2011.

M. Boros, R. Benko, K. Bolcskei, J. Szolcsanyi, L. Bartho et al., Effects of reference analgesics and psychoactive drugs on the noxious heat threshold of mice measured by an increasing-temperature water bath, Basic Clin. Pharmacol. Toxicol, vol.113, pp.385-390, 2013.

S. K. Chan, P. B. Lai, P. T. Li, J. Wong, M. K. Karmakar et al., The analgesic efficacy of continuous wound instillation with ropivacaine after open hepatic surgery, Anaesthesia, vol.65, pp.1180-1186, 2010.

A. M. Ho, M. K. Karmakar, M. Cheung, and G. C. Lam, Right thoracic paravertebral analgesia for hepatectomy, Br. J. Anaesth, vol.93, pp.458-461, 2004.

R. E. Brutcher, C. Kurihara, M. C. Bicket, P. Moussavian-yousefi, D. E. Reece et al., Compounded Topical Pain Creams to Treat Localized Chronic Pain: A Randomized Controlled Trial, Ann. Intern. Med, 2019.